Auxo Firm Directory · Independent Research Profile

Sk Capital

Sk Capital focuses on material sciences, specialty ingredients, and life sciences. Its stated investment types include control buyouts, recapitalizations, growth equity, owner partnerships, and synergistic transactions involving existing portfolio companies.

Key takeaway

What stands out about Sk Capital

Sk Capital publicly describes two investment programs: Flagship for upper mid-sized and large companies, and Catalyst for smaller and mid-sized or lower-middle-market companies. It also describes control, growth, recapitalization, owner-partnership, complex-situation, and portfolio-company-related transactions.[1][2][4][5][11]

What does Sk Capital invest in?

SK Capital is a global private investment firm focused on material sciences, specialty ingredients, and life sciences. The firm states that it was founded in 2007, has raised 7 funds with over $9B in capital commitments as of December 31, 2025, and has owned more than 20 portfolio companies in aggregate.

The official contact page lists an office at 430 Park Avenue, 18th Floor, New York, NY 10022.[1][2][3]

SK Capital states that its typical investments include control buyouts, recapitalizations, growth equity investments, partnerships with existing owners, complex situations with untapped potential, and synergistic transactions involving existing portfolio companies.

The firm also states that it leverages industry, operating, and investment experience to transform businesses through improved strategic positioning, growth, profitability, and lower operating risk.[4][5]

Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.

Public size / criteria information
Sk Capital states that Flagship focuses on upper mid-sized and large companies, while Catalyst is dedicated to smaller and mid-sized or lower-middle-market companies. It reports 7 funds, over $9B in capital commitments as of December 31, 2025, and more than 20 portfolio companies owned in aggregate.

What should a business owner evaluate before considering a transaction with Sk Capital?

An owner evaluating SK Capital can clarify whether the opportunity would be considered through the Flagship or Catalyst program and whether the proposed transaction would be structured as a control buyout, recapitalization, growth investment, owner partnership, or another stated transaction type. The firm’s stated approach also makes its operating, strategic-positioning, growth, profitability, and operating-risk capabilities relevant areas for discussion.

Owners should separately confirm governance and ownership expectations, management participation, the investment horizon, assigned operating resources, financing assumptions, and transaction terms for the specific opportunity.[2][4][5]

01

Which program would pursue the opportunity—Flagship or Catalyst—and what are the applicable enterprise-value, equity-investment, and leverage parameters

The firm publicly distinguishes Flagship and Catalyst by company size, while the cited official about page does not disclose a universal transaction-size range or minimum equity-check criterion.[2]
02

What percentage of ownership and governance rights would SK Capital seek, and what rollover or management-equity participation is expected

SK Capital identifies control buyouts and partnerships with existing owners among its typical investment types; the specific ownership and governance terms for an opportunity should be confirmed directly.[4]
03

What is the anticipated investment horizon and exit approach for this specific company

The cited official strategy page describes investment types and program focus but does not state a universal expected investment holding-period range.[4]

What companies does Sk Capital target?

SK Capital describes two program lanes: Flagship focuses on upper mid-sized and large companies, while Catalyst is dedicated to smaller and mid-sized or lower-middle-market companies.

The cited official about page does not disclose a universal transaction-size range or minimum equity-check criterion.[2]

SK Capital publicly identifies material sciences, specialty ingredients, and life sciences as its sectors of focus.[1][2]

The official contact page lists SK Capital’s office at 430 Park Avenue, 18th Floor, New York, NY 10022.[3]

SK Capital identifies synergistic transactions involving existing portfolio companies as one of its typical investment types. A cited transaction also describes Precera Medical, an SK Capital portfolio company, acquiring the assets and business of Additive Metal Services to add metal injection molding and sinter-based additive manufacturing capabilities.[4][6]

Publicly identified examples include Precera Medical, Apotex, Swixx Biopharma, Isolatek International, and Milestone Environmental. The cited materials record a completed strategic investment in Swixx Biopharma, a completed sale of Isolatek International, and an agreement to sell Milestone Environmental, subject to customary closing conditions and regulatory approvals.[5][8][9]

  • On September 10, 2026, Precera Medical acquired the assets and business of Additive Metal Services.
  • On July 7, 2026, SK Capital reached an agreement to sell Milestone Environmental to I Squared Capital; the transaction was expected to close in Q4 2026 subject to customary closing conditions and regulatory approvals.
  • On July 1, 2026, Apotex completed a strategic transaction with Cumberland Pharmaceuticals to integrate Cumberland’s U.S. branded businesses into Apotex.
  • On June 1, 2026, SK Capital completed a strategic investment in Swixx Biopharma and became the lead investor, alongside Bain Capital Life Sciences and continuing founder and management shareholders.
  • On June 10, 2026, SK Capital completed the sale of Isolatek International to Catchment Capital after a period of ownership described as nearly three years.
[5][6][7][8][9]

What is not clear from Sk Capital's public investment criteria?

The cited official portfolio page entry for Apotex identifies an April 2023 acquisition but does not disclose the transaction value, purchase price, financing terms, or consideration.

The cited official strategy page describes investment types and program focus but does not state a universal expected investment holding-period range.

The cited official about page reports fund count, capital commitments, and portfolio-company scale but does not disclose a universal transaction-size range or minimum equity-check criterion.[2][4][11]

Questions to ask when evaluating Sk Capital as a buyer or investment partner

Which program would pursue the opportunity—Flagship or Catalyst—and what are the applicable enterprise-value, equity-investment, and leverage parameters?
The firm publicly distinguishes Flagship and Catalyst by company size, while the cited official about page does not disclose a universal transaction-size range or minimum equity-check criterion.[2]
What percentage of ownership and governance rights would SK Capital seek, and what rollover or management-equity participation is expected?
SK Capital identifies control buyouts and partnerships with existing owners among its typical investment types; the specific ownership and governance terms for an opportunity should be confirmed directly.[4]
What is the anticipated investment horizon and exit approach for this specific company?
The cited official strategy page describes investment types and program focus but does not state a universal expected investment holding-period range.[4]
Which operating partners and portfolio-company resources would be assigned?
SK Capital states that it uses industry, operating, and investment experience to support strategic positioning, growth, profitability, and lower operating risk; the resources assigned to a specific company should be clarified.[5]
How would add-on acquisitions, sustainability initiatives, capital expenditures, and international expansion be funded?
The firm identifies synergistic transactions involving existing portfolio companies as a typical investment type, while the funding arrangements for a specific opportunity are not established here.[4]
What transaction expenses, financing fees, indemnities, escrow arrangements, earn-outs, or other consideration terms would apply?
The cited official portfolio page entry for Apotex does not disclose transaction value, purchase price, financing terms, or consideration; transaction-specific terms should therefore be confirmed.[11]
Which legal entity would make the investment, and what regulatory or compliance structure governs the transaction?
An SEC Form D identifies SK Capital Partners VI-B, L.P. as a Cayman Islands limited partnership and private equity fund and pooled investment fund; the investing entity and applicable structure for a specific transaction should be confirmed.[10]

Sources & research notes

Public-source research
  1. Official website / firm overview
  2. Official website / firm overview
  3. Geography / market coverage
  4. Transaction / portfolio evidence
  5. Investment approach
  6. Transaction / portfolio evidence
  7. Transaction / portfolio evidence
  8. Transaction / portfolio evidence
  9. Transaction / portfolio evidence
  10. SEC filing / regulatory record
  11. Public disclosure information
Prepared and reviewed by: Auxo Capital AdvisorsEvidence standard: Public-source verification

How this profile was researched

Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.

Independent profile & regulatory context

Independent research profile

This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.

Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.

Broker-dealer and securities disclosure

Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.

Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.

Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.

Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.